First PFAS "Forever Chemicals" Consumer-Initiated Blood Test With Physician Consult Launches on questhealth.com
Quest Diagnostics (NYSE:DGX) launches a groundbreaking consumer-initiated blood test for PFAS chemicals, offering consultation with a physician. The test targets individuals at risk of elevated PFAS exposure, as identified by National Academies of Sciences, Engineering, and Medicine. Organizations can also utilize the test for workforce, community, and research population screening.
The introduction of a consumer-initiated, physician-ordered blood test for PFAS (per- and polyfluoroalkyl substances) by Quest Diagnostics represents a significant advancement in individual health monitoring and public health awareness. PFAS are a group of manufactured chemicals that have been linked to various health issues, including cancer, immune system effects and hormonal disruptions. The ability to detect and measure these chemicals in individuals provides valuable data for epidemiological studies and potential regulatory actions.
From a medical research perspective, the test could lead to increased detection rates of PFAS exposure, prompting further research into the health implications of these chemicals. Longitudinal studies could be designed to monitor the health outcomes of individuals with known PFAS levels, thereby contributing to a deeper understanding of the risks associated with exposure. Furthermore, the test could serve as a baseline for evaluating the effectiveness of interventions aimed at reducing PFAS exposure.
Quest Diagnostics' release of this test could potentially open up a new market segment focused on environmental health testing. As awareness of PFAS and their potential dangers grows, consumer demand for such testing services is likely to increase. This move may position Quest Diagnostics ahead of competitors in the diagnostic industry. The service could appeal to a broad range of stakeholders, including individuals in affected communities, employers concerned about occupational health and researchers studying PFAS impacts.
Moreover, this development could have implications for the stock market, as investors may view the introduction of innovative testing services as a growth opportunity for Quest Diagnostics. The company could see an increase in revenue streams if the test is widely adopted. However, it is essential to monitor how the market responds to this new offering and whether Quest Diagnostics can effectively capitalize on the increasing public concern over environmental contaminants.
The economic implications of such a test are multifaceted. On one hand, it could lead to increased healthcare spending as individuals seek to understand their PFAS exposure levels and potentially require treatment or monitoring for related health conditions. On the other hand, it could also drive policy changes that lead to stricter regulations on PFAS emissions and usage, potentially impacting industries that manufacture or use these chemicals. Such regulations could have downstream economic effects, including shifts in industry practices, job market changes and alterations in the competitive landscape.
In the long term, the availability of PFAS testing could influence public health policies and healthcare costs associated with exposure-related illnesses. If the test results in more proactive health management and prevention strategies, it could ultimately lead to cost savings for the healthcare system. However, if the test leads to the identification of widespread PFAS exposure without effective treatment or mitigation strategies, it could result in increased long-term healthcare costs.
03/04/2024 - 02:45 PM
Directed at individuals who may be at risk of elevated PFAS exposure, the new test detects and measures PFAS identified by National Academies of Sciences, Engineering, and Medicine Organizations interested in workforce, community, and research population testing may also access the test SECAUCUS, NJ / ACCESSWIRE / March 4, 2024 / Quest Diagnostics (NYSE:DGX), the world's leader in diagnostic information services, announced the availability of the first consumer-initiated, physician-ordered blood-draw test for PFAS chemicals with the option to confer over the phone with a physician about the results.
Available at questhealth.com , the new test, PFAS (Forever Chemicals) Test Panel , is performed by Quest Diagnostics to identify the level of potentially harmful chemicals called per- and polyfluorinated alkyl substances (PFAS) - also known as "forever chemicals" because they can accumulate and linger in the environment and body.
According to the U.S. Centers for Disease Control and Prevention , health effects potentially associated with PFAS exposure include increases in cholesterol levels, decreases in birth weight, lower antibody response to vaccines, kidney and testicular cancer, pregnancy-induced hypertension, preeclampsia, and changes in liver enzymes.
"Scientists and the general public are increasingly aware that PFAS may be dangerous to human health, but access to quality, convenient testing to assess exposure is limited," said Jack Kain, PharmD, director and medical science liaison of Drug Monitoring and Toxicology, Quest Diagnostics. "Our PFAS blood test is based on the latest science and aligns with several facets of new CDC guidance as well as recommendations from the National Academies of Sciences, Engineering, and Medicine. Not everyone needs a PFAS test, but people at high risk of elevated exposure may benefit from greater access to the insights provided by this novel test."
Testing may be right for people who likely have had elevated exposure to PFAS. These may include people who have been exposed to PFAS while on the job, such as firefighters, or who used a water supply near a commercial or industrial location, as well as those living near a facility that manufactures fluorochemicals or areas of documented PFAS environmental contamination.
The new test from Quest features several unique innovations. It is the first PFAS blood test available as a consumer-initiated test with physician consult to report a sum of PFAS chemicals based on level of health risks identified by the National Academies of Sciences, Engineering, and Medicine (NASEM). The physician consultation, available to any individual who purchases the test, involves a telephone discussion between the individual and a third-party licensed physician about the results. In addition to providing personalized results, each easy-to-read test report includes information on ways to reduce exposure risk and can be shared with a personal physician.
The test is also widely available; individuals can visit most of Quest's approximately 2,100 patient service centers in the U.S. for a blood draw*.
In addition to offering the test to consumers, Quest is making the test available via B2B channels for organizations seeking workforce, community, or research-based testing for at-risk populations due to concerns about elevated PFAS exposures. The company plans to introduce a version of the test specifically for physicians to aid patient care later this year.
PFAS Testing Based on the Latest Science
The Quest test aligns with several recommendations from NASEM on PFAS testing, including:
Use of serum or plasma blood specimens (blood taken from an arm) instead of capillary blood specimens (from a fingerstick). Quantifying levels of several specific PFAS chemicals identified for potential health risks. Reporting the sum of those levels by three general risk categories. According to NASEM, individuals whose results are in the third, or highest, category (levels of 20 ng/mL or above) may benefit from additional medical care, such as thyroid function testing and assessment of signs of kidney and testicular cancer. While most individuals have some level of PFAS exposure, an estimated 9% of Americans have PFAS levels of 20 ng/mL or higher, typically due to environmental or occupational exposure.
In January 2024, the CDC's Agency for Toxic Substances and Disease Registry unveiled updated guidance to help providers and patients consider PFAS blood testing, based largely on the NASEM recommendations.
About PFAS
PFAS chemicals are associated with $22 billion in healthcare costs, according to a study published in the Journal of the Endocrine Society[1]. Some individuals are at increased risk of prolonged exposure due to certain environmental and occupational factors. This includes firefighters, people living near industrial locations such as manufacturing plants, military bases, and airports, and those living in communities with known PFAS environmental contamination. According to the Environmental Working Group, more than 4,600 communities across the U.S. are at risk, as of August 2023.
Human health effects from exposure to low environmental levels of PFAS are uncertain. More research is needed to assess the human health effects of exposure to PFAS. Finding PFAS in an individual's blood does not mean that the levels of PFAS harmed the individual's health. For more information about PFAS chemicals see:
Consumer-Initiated Testing with a Physician Consult questhealth.com . Unlike traditional direct-to-consumer tests, each test involves physician oversight and consultation on request with a licensed physician. Specifically, when an individual purchases a PFAS test online, a physician from PWNHealth, an independent, third-party physician network, will review the request and place an order. Once the order is submitted, an individual can schedule an appointment for a blood draw at a Quest Diagnostics patient service center. When testing is completed, results are provided in an easy-to-read report on a secure patient portal. An individual may then request a separate telephone consult with a PWNHealth physician to review the results. In addition, a PWNHealth care coordinator will actively contact any individual whose test results suggest elevated PFAS exposure (20ng/mL or higher) to recommend a physician consultation.
A Solution for Population Testing Public Health Departments, Employers, Military Sites, Municipalities, and other Organizations PFAStesting@questdiagnostics.com .
*PFAS blood testing does not identify the sources of a person's exposure or predict future health outcomes. This test assesses PFAS levels at the time of the blood sample collection. This PFAS test is not intended for use in the diagnosis of any disease or other conditions, or for use in the cure, mitigation, or treatment of any disease or condition. Only a physician can diagnose a health condition or outcome. This test is not appropriate for forensic use. Not available for purchase in AK, AZ, HI, or NY.
** In January 2024, the CDC provided new information on its website that recognizes the value of PFAS blood testing by a CLIA-certified laboratory. As knowledge and guidelines about PFAS ("forever chemicals") and PFAS testing continue to evolve, questhealth.com may update its test offering accordingly.
About Quest
About Quest Diagnostics www.QuestDiagnostics.com
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.
1 Leonardo Trasande, Roopa Krithivasan, Kevin Park, Vladislav Obsekov, Michael Belliveau, Chemicals Used in Plastic Materials: An Estimate of the Attributable Disease Burden and Costs in the United States, Journal of the Endocrine Society , Volume 8, Issue 2, February 2024, bvad163, https://doi.org/10.1210/jendso/bvad163
SOURCE Quest Diagnostics
For further information: Jillian Flanagan (Media): mediacontact@questdiagnostics.com or Shawn Bevec (Investors): 973-520-2900
View additional multimedia and more ESG storytelling from Quest Diagnostics on 3blmedia.com.
Contact Info: info@3blmedia.com
SOURCE: Quest Diagnostics
press release on accesswire.com
What type of test has Quest Diagnostics (NYSE:DGX) launched?
Quest Diagnostics (NYSE:DGX) has launched the first consumer-initiated, physician-ordered blood-draw test for PFAS chemicals.
Who may benefit from the new test offered by Quest Diagnostics (NYSE:DGX)?
Individuals at risk of elevated PFAS exposure, as identified by National Academies of Sciences, Engineering, and Medicine, can benefit from the new test.
Can organizations utilize the test offered by Quest Diagnostics (NYSE:DGX)?
Yes, organizations interested in workforce, community, and research population testing can also access the test.
What additional service does Quest Diagnostics (NYSE:DGX) offer along with the test?
Quest Diagnostics (NYSE:DGX) offers the option for consumers to confer over the phone with a physician.
